SCHEMBL7150889

SCHEMBL7150889

Cc1ccc(NS(=O)(=O)CCSc2nc3ccccc3s2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.62
HSD17B10 Q99714 2/20 0.62
MAPT P10636 5/20 0.58
LMNA P02545 4/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
KMT2A Q03164 3/20 0.58
HTT P42858 2/20 0.58
CYP1A2 P05177 4/20 0.55
CYP2D6 P10635 3/20 0.55
CYP3A4 P08684 3/20 0.54
GAA P10253 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 3/20 0.51
IDO1 P14902 1/20 0.51
MEN1 O00255 2/20 0.50
POLB P06746 2/20 0.50
HTR1A P08908 1/20 0.50
HTR2A P28223 1/20 0.50
HTR7 P34969 1/20 0.50
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7144757 0.93 ALDH1A1 (0.57) ALDH1A1HSD17B10MAPTLMNASMN1; SMN2
SCHEMBL7144795 0.92 ALDH1A1 (0.56) ALDH1A1HSD17B10MAPTLMNASMN1; SMN2
SCHEMBL7147361 0.88 ALDH1A1 (0.47) ALDH1A1HSD17B10MAPTLMNASMN1; SMN2
SCHEMBL7151678 0.88 MAPT (0.56) ALDH1A1HSD17B10MAPTLMNASMN1; SMN2
SCHEMBL7153247 0.88 ALDH1A1 (0.59) ALDH1A1HSD17B10MAPTLMNASMN1; SMN2
SCHEMBL7149659 0.88 ALDH1A1 (0.59) ALDH1A1HSD17B10MAPTLMNASMN1; SMN2
SCHEMBL7146714 0.84 ALDH1A1 (0.62) ALDH1A1HSD17B10MAPTLMNASMN1; SMN2
SCHEMBL7149325 0.83 MAPT (0.53) MAPTLMNASMN1; SMN2POLBTP53
SCHEMBL7153246 0.82 ALDH1A1 (0.43) ALDH1A1HSD17B10MAPTLMNASMN1; SMN2
SCHEMBL7147570 0.81 ALDH1A1 (0.54) ALDH1A1HSD17B10MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed
WO-2003043577-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 ALDH1A1 2919/4885HSD17B10 2088/4885MAPT 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.